PREDICTIVE FACTORS OF LONGITUDINAL BONE LOSS IN PATIENTS TREATED WITH AROMATASE INHIBITORS FOR BREAST CANCER

被引：0
|
作者：
Fowler, J. [1 ,2 ]
Mitchell, K. [1 ,2 ]
Bukhari, M. [1 ,3 ]
机构：
[1] Univ Lancaster, Fac Hlth & Med, Lancaster, England
[2] Univ Hosp Morecambe Bay, Lancaster, England
[3] Univ Hosp Morecambe Bay, Rheumatol Dept, Lancaster, England
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷
关键词：
D O I：
10.1136/annrheumdis-2014-eular.2415
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0473
引用
收藏
页码：764 / 765
页数：2
相关论文
共 50 条
  • [31] The Effects Of Baduanjin On Menopausal Symptoms In Patients With Breast Cancer Treated With Aromatase Inhibitors
    Hou, Xiaohui
    Lan, Hao
    Liao, Jingwen
    Hu, Min
    [J]. MEDICINE & SCIENCE IN SPORTS & EXERCISE, 2024, 56 (10) : 1083 - 1083
  • [32] Impact of adjuvant aromatase inhibitors on bone mineral density in breast cancer patients
    Lai, C. N.
    Correa, P. D.
    Alhasso, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] Single cell characterization of longitudinal biopsies from breast cancer patients treated with the aromatase inhibitors letrozole and exemestane in sequence
    Ghannoum, Salim
    Steen, Chloe
    Fongard, Marie
    Bjornstad, Marius
    Reitsma, Laurens
    Geisler, Stephanie
    Seyedzadeh, Manouchehr
    Buvarp, Unn-Cathrin
    Loeng, Marie
    Luders, Torben
    Lambrechts, Diether
    Lyngra, Marianne
    Kristensen, Vessela
    Geisler, Jurgen
    Tekpli, Xavier
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [34] Erratum to: Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper
    R. Rizzoli
    J. J. Body
    A. DeCensi
    J. Y. Reginster
    P. Piscitelli
    M. L. Brandi
    [J]. Osteoporosis International, 2012, 23 (11) : 2577 - 2577
  • [35] Risk factors for incident fracture in patients with breast cancer treated with aromatase inhibitors: B-ABLE cohort
    Garcia-Giralt, N.
    Pineda-Moncusi, M.
    Ovejero, D.
    Aymar, I
    Soldado-Folgado, J.
    Campodarve, I
    Rodriguez-Morera, J.
    Nogues, X.
    [J]. REVISTA DE OSTEOPOROSIS Y METABOLISMO MINERAL, 2020, 12 (01) : 7 - 13
  • [36] Management of Aromatase Inhibitor-Induced Bone Loss in Breast Cancer Patients
    Husnoo, N.
    Abbas, S.
    [J]. BRITISH JOURNAL OF SURGERY, 2016, 103 : 134 - 135
  • [37] Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients
    Foglietta, Jennifer
    Inno, Alessandro
    de Iuliis, Francesca
    Sini, Valentina
    Duranti, Simona
    Turazza, Monica
    Tarantini, Luigi
    Gori, Stefania
    [J]. CLINICAL BREAST CANCER, 2017, 17 (01) : 11 - 17
  • [38] Effects of Aromatase inhibitors on bone mineral density and trabecular bone score in patients with breast cancer
    Dabbagh, V.
    Shandiz, F. Homaee
    Kermani, A. Taghizadeh
    Javan, F. Nesari
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S465 - S465
  • [39] EFFECT OF AROMATASE INHIBITORS ON BONE MINERAL DENSITY AND TRABECULAR BONE MICROARCHITECTURE IN PATIENTS WITH BREAST CANCER
    Tsagareli, M.
    Giorgadze, E.
    Sulikashvili, T.
    Jeiranashvili, N.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2021, 32 (SUPPL 1) : S189 - S189
  • [40] Aromatase, aromatase inhibitors, and breast cancer
    Chumsri, Saranya
    Howes, Timothy
    Bao, Ting
    Sabnis, Gauri
    Brodie, Angela
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2011, 125 (1-2): : 13 - 22
12345